We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

CIMB:MYXCIMB Group Holdings Bhd Analysis

Data as of 2026-03-11 - not real-time

IDR 1,755.00

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

PT Bank CIMB Niaga trades at a **low P/E ratio** far below the industry average and a **price‑to‑book well under one**, signaling a clear valuation discount. The stock also offers an **attractive dividend yield near 9%** with a payout ratio comfortably below 60%, suggesting the dividend is sustainable.
The technical picture shows a **bullish trend** as the price sits above the 20‑day and 50‑day SMAs, while the 30‑day volatility is elevated, indicating ample room for price movement. The RSI is in oversold territory and the MACD shows a bearish divergence, but the price is above the key support level and volume is on an upward trajectory, hinting at short‑term upside potential.
Risk‑wise, the beta is near zero, giving the stock a **defensive market profile**, yet the 30‑day volatility and negative operating cash flow introduce medium‑level concerns. Sector‑specific regulatory exposure and Indonesia’s emerging‑market dynamics add moderate geographic and regulatory risk, but the combination of **value pricing, strong dividend income, and low market sensitivity** supports a positive outlook across horizons.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • RSI indicates oversold conditions with near‑term upside
  • Price is comfortably above short‑term support
  • Rising volume supports momentum

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Significant valuation discount relative to peers
  • High dividend yield provides income cushion
  • Negative operating cash flow warrants caution

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Sustained dividend income at attractive yield
  • Low beta offers defensive characteristics
  • Valuation gap versus industry suggests long‑run upside

Key Metrics & Analysis

Financial Health

Revenue Growth6.30%
Profit Margin38.72%
P/E Ratio6.4
ROE12.46%
ROA1.89%
P/B Ratio0.8
Op. Cash FlowIDR-6691461005312
Industry P/E17.3

Technical Analysis

TrendBullish
RSI34.2
SupportIDR 1,720.00
ResistanceIDR 1,905.00
MA 20IDR 1,833.50
MA 50IDR 1,823.70
MA 200IDR 1,749.43
MACDBearish
VolumeIncreasing
Fear & Greed Index76.91

Valuation

Target PriceIDR 2,166.00
Upside/Downside23.42%
GradeUndervalued
TypeValue
Dividend Yield8.95%

Risk Assessment

Beta0.08
Volatility21.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.